Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04295863 · ClinicalTrials.gov registry record · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
A Phase 1 study of Metastatic Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 264
- Enrollment target
- 2
- Study locations
NCT04295863 is a Phase 1 study of Metastatic Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 264 participants, below the 441-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04295863, a Phase 1 study of Metastatic Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 264 participants
- Enrollment target
- 2
- Study locations
Study Summary
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Conditions Studied
Interventions
- DRUG Nivolumab Standard
- DRUG Pembrolizumab Standard
- DRUG Nivolumab Extended
- DRUG Pembrolizumab Extended
Study Locations (2)
Illinois
- University Of Chicago Medicine Comprehensive Cancer Center - Chicago
Wisconsin
- SSM Health Cancer Care - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2020-06-25 |
| Est. Completion | 2026-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04295863
The ClinicalTrials.gov registry entry for NCT04295863 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 441-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (40% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab Standard is the first listed.
NCT04295863 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04295863 about?
NCT04295863 is a clinical study titled "Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers". A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from...
What is the current status of trial NCT04295863?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 264 participants. The study started on 2020-06-25. Estimated completion is 2026-04-12.
What conditions does trial NCT04295863 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT04295863?
The interventions under investigation include: Nivolumab Standard (DRUG), Pembrolizumab Standard (DRUG), Nivolumab Extended (DRUG), Pembrolizumab Extended (DRUG).
Who is sponsoring clinical trial NCT04295863?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04295863 being conducted?
This trial has 2 study locations across Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.